Organization
MedImmune LLC
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
MedImmune LLC
... AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as ...
... Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination ...
... New Studies in NSCLC Patients in Collaboration with Moffitt Cancer Center and MedImmune - SAN CARLOS, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, ...
... with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in ...
... announced that the Company has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly ...
... antigens hTERT, WT1, and PSMA, which are over-expressed in multiple tumor types. MedImmune, Regeneron and Genentech have all turned to Inovio's DNA-based immunotherapy products to ...
... Biogen Inc, Evotec AG, Genmab A/S, H. Lundbeck A/S, ICB International Inc, MedImmune LLC, Neuropore Therapies Inc, nLife Therapeutics SL, Prothena Corp Plc, QR Pharma ...
... Enzo Life Sciences (US), Master Diagnóstica (Spain), TissueGnostics (Austria), Bio SB (US), MedImmune (US), Cernostics (US), Zenalux Biomedical (US), 3DHISTECH (Hungary), Lunaphore Technologies (Switzerland), BioGenex ...
... the ESMO Asia 2017 Congress in Singapore, 17-19 November 2017, AstraZeneca and MedImmune, its global biologics research and development arm, will share ground-breaking results from ...
... AstraZeneca(NYSE: AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved ...
... for the region. Thought leaders from the National Institutes of Health (NIH), MedImmune , Vibrent Health , Virginia Tech , the National Science Foundation (NSF), ...
... 2, S. Althammer 1, R. Huss 1 1 Definiens, Munich, Germany; 2 MedImmune, Gaithersburg MD, USA Friday, Nov. 10: 12:30 - 2 p.m. (Lunch) Friday, ...
... caused by human papillomavirus (HPV) types 16 and 18 and licensed to MedImmune, the global Research and Development arm of AstraZeneca, also led to a ...
... AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific ...
... HPV-Related Head & Neck Cancer (Phase 1/2) In May, Inovio announced that MedImmune, AstraZeneca's global biologics research and development arm, commenced a new clinical trial ...
... AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and ...
... AstraZeneca and Medimmune, its global biologics research and development arm, continue to demonstrate their progress ...
... AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US ...
... AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced that the European ...
... Board Members: Kathleen L. Coelingh, Ph.D. was Senior Director, Medical Affairs at MedImmune, the biologics unit of AstraZeneca. Prior to that while at the NIH ...
Want to see the full history on MedImmune LLC? Upgrade to RelSci Pro now!
Start My Free Trial